Guarded N.I.H. Nominee Faces Sharp Questions on Vaccines and Research Cuts
Jay Bhattacharya, a health economist, gained prominence during the Covid pandemic when he argued against lockdowns.
Research Identifies Key Antibodies for Development of Broadly Protective Norovirus Vaccine
Researchers identify key antibodies that bring us one step closer to treatment and vaccine for norovirus, a prevalent and difficult virus to prevent.
NIH director nominee outlines his goals to improve public health
A relatively sedate Senate Health, Education, Labor and Pensions Committee confirmation hearing for National Institutes of Health Director-nominee Dr. Jay Bhattacharya revealed his five goals to ...
The Citizen5d
3 new cases of Mpox confirmed in South Africa
Health authorities have urged communities to be vigilant as three new Mpox cases were confirmed in Gauteng, marking the first ...
MedPage Today on MSN3dOpinion
'No One Wants to Lose Their Job': What We Heard This Week
"No one wants to lose their job. In the absence of any guidance, opinions fly about what we should do." -- An anonymous ...
Daily Hampshire Gazette2d
A moment with Dr. Fauci: Expert who became household name during pandemic featured guest at Amherst College LitFest
When the Morbidity and Mortality Weekly Report landed on Dr. Anthony Fauci’s desk in June 1981, he had no idea it would be ...
Omalizumab treats multi-food allergy better than oral immunotherapy, study finds
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...
Verywell Health on MSN18h
Food Allergy vs. Intolerance: How to Tell the Difference
Food allergy, intolerance, and sensitivity generally differ based on whether or not IgE, a protein the body can make against ...
Scientific American20h
On COVID’s Fifth Anniversary, Scientists Reflect on Mistakes and Successes
Public health experts discuss lessons learned from the U.S. response to the COVID pandemic, on topics ranging from school ...
News Medical on MSN3d
Omalizumab outperforms oral immunotherapy in treating multi-food allergy
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...
Taiwan News2d
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC ...
News Medical on MSN1d
Feeding infants diverse foods early may cut allergy risk, study reveals
Early dietary diversity in infants may reduce the risk of food allergies by promoting immune tolerance and gut microbiome ...